How Nepal silences women in public life

Nepal, April 9 -- ''To ruin a woman's life, all it takes is assassinating her character.'' These were National Assembly Vice-President Leela Kumari Bhandari's first public statement upon assuming off... Read More

Numerous clips of Vijay's unreleased last film Jana Nayagan leaked online; fans claim cybercrime complaint filed

India, April 9 -- Actor and Tamilaga Vettri Kazhagam (TVK) chief Vijay seems to be running into one hurdle after another, with the latest one being that portions of his film are being leaked online. E... Read More

Johnnie Walker Luxe Blended Water x Virat Kohli campaign taps evolving consumer mindset around success and progress

New Delhi, April 9 -- What comes after success? For Virat Kohli, and a new, self-driven India - the answer isn't just celebration. It's continuation. In a bold power-play where Icon meets Icon, Johnn... Read More

Weekend Drive by Hormazd Sorabjee: Catching the son rise

India, April 9 -- My 91-year-old mother, great-grandmother to five, has always wanted to do a road trip from Delhi to Mumbai. Both cities have been home to her for almost 50 years, and she's shuttled ... Read More

Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 9 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More

• ««
• «
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• 42
• 43
• 44
• »
• »»